A summary of clinical researches with the aim of editing or knocking down aberrant expression of different target genes relevant to IGF signaling pathway in various human cancers via employing CRISPR/Cas9 and siRNA gene-editing tools are demonstrated in Tables 6, 7, respectively. This evidence concerns the gene IGF1 and cancer.